Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Surgery, percutaneous ablation and liver transplantation are the only curative treatment modalities for HCC. However, the majority of patients have unresectable disease at diagnosis. Therefore, effective treatment options fo...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:World journal of gastroenterology : WJG Ročník 21; číslo 13; s. 3843 - 3849
Hlavný autor: Song, Myeong Jun
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 07.04.2015
Predmet:
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - pathology
Hepatic Artery
Humans
Infusions, Intra-Arterial
Liver Neoplasms - drug therapy
Liver Neoplasms - mortality
Liver Neoplasms - pathology
Neoplasm Staging
Treatment Outcome
Hepatocellular carcinoma
Treatment efficacy
Advanced stage hepatocellular carcinoma
Hepatic arterial infusion chemotherapy
Sorafenib
ISSN:2219-2840
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Surgery, percutaneous ablation and liver transplantation are the only curative treatment modalities for HCC. However, the majority of patients have unresectable disease at diagnosis. Therefore, effective treatment options for patients with advanced HCC are required. In advanced HCC, according to current international guidelines, sorafenib, a molecular targeted agent, is the standard treatment. However, alternative treatment modalities are required because of the low response rates and unsuitability of molecular agents in real practice. In various treatment modalities, mostly in Asia, hepatic arterial infusion chemotherapy (HAIC) has been applied to advanced HCC with a view to increasing the therapeutic efficacy. HAIC provides direct drug delivery into the tumor feeding vessels and also minimizes systemic toxicities through a greater first-pass effect in the liver. However, the sample sizes of studies on HAIC have been small and large randomized trials are still lacking. In this article, we describe the treatment efficacy of HAIC for advanced stage HCC and discuss future therapeutic possibilities.
Bibliografia:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2219-2840
DOI:10.3748/wjg.v21.i13.3843